Concord Biotech Ltd. (CONCORDBIO) AI Stock Analysis

Top Page

Concord Biotech Ltd.

(NSE:CONCORDBIO)

Select Model

Rating:79Outperform

Price Target:INR 1,426.00▲(14.51% Upside)

Action:upgraded

Date:08/19/26

Strong financial performance, led by excellent balance sheet strength and cash generation, is the main positive driver. Bullish technical indicators add support while high valuation metrics act as the key constraint.

Positive Factors

Conservative balance sheetThe exceptionally conservative capital structure reduces financial risk and limits interest-related pressure on earnings. Minimal debt also preserves flexibility to fund capacity, research, or other strategic priorities internally while providing resilience if operating conditions weaken.

Negative Factors

2026 revenue declineThe reversal from several years of revenue expansion indicates that demand or execution momentum has become less consistent. If the decline persists, slower scale growth could limit operating leverage, reduce reinvestment capacity, and weaken the pace of earnings recovery.

Concord Biotech Ltd. (CONCORDBIO) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 130.31B
Dividend Yield: 0.61%
Average Volume (3M): 47.82K
Price to Earnings (P/E): 46.2
Beta (1Y): 0.98
Revenue Growth: 4.02%
EPS Growth: -12.81%
Country: India
Employees: 1,624
Sector: General
Sector Strength: 55
Industry: Biotechnology

Concord Biotech Ltd. Business Overview & Revenue Model

Company Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in...

Concord Biotech Ltd. Financial Statement Overview

Summary

Strong revenue growth and improving margins through 2025, robust balance sheet with low debt and rising equity, plus consistently positive and growing cash flows support solid financial profile despite minor 2026 projection concerns.

Income Statement

78Positive

Balance Sheet

92Very Positive

Cash Flow

85Very Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	11.08B	10.55B	12.00B	10.17B	8.53B	7.13B
Gross Profit	5.66B	4.42B	7.68B	6.67B	6.61B	5.41B
EBITDA	4.25B	4.19B	5.14B	4.40B	3.54B	2.79B
Net Income	2.75B	2.61B	3.72B	3.08B	2.40B	1.75B
Balance Sheet
Total Assets	0	22.35B	20.34B	17.01B	15.14B	13.13B
Cash, Cash Equivalents and Short-Term Investments	4.32B	4.16B	3.18B	2.86B	1.81B	1.62B
Total Debt	0	23.16M	29.69M	97.38M	315.47M	624.93M
Total Liabilities	-20.15B	2.20B	2.22B	1.74B	2.24B	2.10B
Stockholders Equity	20.15B	20.17B	18.13B	15.27B	12.90B	11.03B
Cash Flow
Free Cash Flow	975.85M	1.74B	1.36B	1.80B	1.01B	519.70M
Operating Cash Flow	1.51B	2.69B	2.47B	2.65B	2.46B	2.07B
Investing Cash Flow	-212.84M	-1.45B	-1.63B	-1.55B	-1.58B	-1.12B
Financing Cash Flow	-1.13B	-1.13B	-986.67M	-992.15M	-852.19M	-1.00B

Concord Biotech Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price1245.30

Price Trends

50DMA1419.74Negative

100DMA1378.33Negative

200DMA1264.06Negative

Market Momentum

MACD-43.83Positive

RSI39.91Neutral

STOCH20.43Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Negative. The current price of 1245.30 is below the 20-day moving average (MA) of 1321.16, below the 50-day MA of 1419.74, and below the 200-day MA of 1264.06, indicating a bearish trend. The MACD of -43.83 indicates Positive momentum. The RSI at 39.91 is Neutral, neither overbought nor oversold. The STOCH value of 20.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CONCORDBIO.

Concord Biotech Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:CONCORDBIO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:CONCORDBIO	79Outperform	INR 130.28B	46.20	―	0.61%	4.02%	-12.81%
IN:ANTHEM	77Outperform	INR 466.85B	80.86	―	0.24%	―	―
IN:DCAL	56Neutral	INR 22.76B	33.34	―	―	-20.86%	-34.51%
IN:SYNGENE	56Neutral	INR 162.52B	86.98	―	0.31%	-5.99%	-60.30%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:BIOCON	49Neutral	INR 573.10B	103.47	―	0.14%	9.83%	5.07%
IN:PANACEABIO	47Neutral	INR 19.17B	-270.04	―	―	10.26%	-162.02%

* General Sector Average

Performance Comparison

IN:CONCORDBIO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:CONCORDBIO	Concord Biotech Ltd.	1245.30	-214.11	-14.67%
IN:BIOCON	Biocon Limited	352.00	-24.75	-6.57%
IN:DCAL	Dishman Carbogen Amcis Ltd.	145.15	-146.50	-50.23%
IN:PANACEABIO	Panacea Biotec Limited	312.95	-119.10	-27.57%
IN:SYNGENE	Syngene International Ltd.	402.60	-253.29	-38.62%
IN:ANTHEM	Anthem Biosciences Limited	828.45	127.63	18.21%

Concord Biotech Ltd. Corporate Events

Concord Biotech Approves 1:1 Bonus Issue and Doubles Authorised Share Capital

Sep 23, 2026

Concord Biotech Limited’s board has approved a 1:1 bonus issue, granting shareholders one additional equity share for every fully paid-up share held as of a record date to be set later. The bonus shares will be issued by capitalizing the compan...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 19, 2026

Concord Biotech Ltd. AI Stock Analysis

Top Page